Haemophilus ducreyi expresses a conserved hemoglobin-binding outer-membrane protein (HgbA). To test the role of HgbA in pathogenesis, we infected 9 adults with isolate 35000 and its isogenic hgbA-inactivated mutant (FX504) on their upper arms in a double-blinded, escalating dose-response study. Papules developed at similar rates at sites inoculated with the mutant or parent. The pustule-formation rate was 55% (95% confidence interval [CI], 30.8%-78.5%) at parent sites and 0 (95% CI, 0-10.5%) at mutant sites ( ). The recovery P ! .0001 rate of H. ducreyi from surface cultures was 16% ( ) from parent sites and 0 ( ) n = 142 n = 213 from mutant sites ( ). H. ducreyi was recovered at biopsy from 6 of 7 parent sites and P ! .0001 from 0 of 3 mutant sites. The results indicate that hemoglobin may be a critical source of heme or iron for the establishment of H. ducreyi infection in humans.
in H. ducreyi 35000 [6] . In contrast to the parent 35000, FX504 cannot grow on plates on which hemoglobin is the sole source of heme [6] .
To study H. ducreyi pathogenesis, we had developed an experimental model of infection in human subjects, described elsewhere [10] [11] [12] . Human volunteers are inoculated on the skin of the upper arm with H. ducreyi via puncture wounds made with an allergy-testing device. Because of concerns for subjects' safety, infection is terminated at the pustular stage of disease, before ulceration; however, subjects may be safely infected for р14 days. Our cumulative experience with strain 35000 showed that inoculation of ∼27 cfu results in a papule-formation rate of 90% and a pustule-formation rate of 50%, and inoculation of ∼55 cfu achieves a 70% pustule-formation rate; inoculation of ∼100 cfu results in a 90% pustule-formation rate [13] , and the kinetics of papule and pustule-formation resemble natural infection. Inoculation of an estimated delivered dose (EDD) of у1000 cfu causes pustules that progress too rapidly to mimic natural infection [10] . Lesion outcomes (papule, pustule, resolved) at multiple sites inoculated with the same dose of an isolate in an individual subject are independent [12] . Thus, site, rather than subject, is used as the unit of measure for statistical comparisons of isogenic mutants and parents [9] .
We tested the role of the HgbA receptor in the ability of H. ducreyi to cause infection in humans. The virulence of an isogenic pair of isolates was tested in a double-blinded, escalating dose-response study. We compared the pustule-formation rate, cellular infiltrate, and recovery of bacteria from lesions produced by inoculation with the mutant and the parent.
Materials and Methods

Preparation of the inoculum. H. ducreyi 35000 (ATCC 33922)
was isolated in Winnipeg, Canada, in the 1970s [10] . The construc-tion and characterization of the HgbA receptor-deficient mutant, FX504, was described elsewhere [6] . Lipo-oligosaccharide (LOS) and outer-membrane proteins were prepared from 35000 and FX504, as described elsewhere [14, 15] . Outer-membrane proteins were subjected to analysis by use of SDS-PAGE on either 12.0% or 7.5% acrylamide gels, as described elsewhere [5, 16] . LOS was analyzed by use of SDS-PAGE on 12% gels and by use of silver staining or Western blot analysis with monoclonal antibody 3F11, which binds to the terminal portion of H. ducreyi LOS [15, 17] .
Human volunteers. Nine healthy adults (5 women, 4 men; 6 white, 3 black; age range, 23-57 years; mean , age ‫ע‬ SD 36.6 ‫ע‬ ) volunteered for the study. An additional volunteer gave con-11.6 sent but was excluded because of a history of esophageal cancer. Details of enrollment procedures and exclusion criteria have been described elsewhere [10, 11] .
Human challenge protocol. The experimental challenge protocol, preparation and inoculation of the bacteria, and clinical observations were as described elsewhere [9] [10] [11] [12] . Although we did not experimentally determine the actual delivered dose, throughout the text we will refer to the EDD as being 1000-fold less than the average number of cfu loaded on the tines [11, 12, 18] .
Subjects were infected at 6 sites. On one arm, 3 sites were inoculated with 2-fold serial dilutions of FX504. On the other arm, 2 sites were inoculated with 35000 and 1 site with the highest dose of the heat-killed mutant. To blind the study, the 6 suspensions containing bacteria were arranged in random order, given a code number, and inoculated at identical sites on each subject in each iteration. The clinicians who evaluated the subjects were unaware of the identity of the suspensions. Subjects were observed until they reached 1 of 3 predefined clinical end points: 14 days after inoculation, development of a painful pustule, or resolution of infection at all sites. When a clinical end point was reached, the code was broken, and biopsy specimens were removed from р2 sites with active disease (1 inoculated with 35000 and 1 with FX504), if present. The subjects were then treated with 2 doses of oral ciprofloxacin (500 mg), given 12 h apart, or a single dose of azithromycin (1000 mg).
Study design. A modification of an escalating dose-response study was used to examine the virulence of FX504 [9] . The rationale for the design is described elsewhere [9, 12] . For the first experiment, we enrolled 3 subjects. The target EDD of the parent was 55 cfu, and the target EDDs for the mutant were 25, 50, and 100 cfu. If we observed similar pustule-formation rates at sites infected with both the mutant and the parent, we challenged 3 more subjects in a similar manner. If the results were confirmed, we concluded that there was no major difference in the virulence of the mutant and the parent, and we terminated the trial.
If the mutant formed pustules at a lower rate than did the parent, a power analysis was done to determine the number of sites that must be inoculated with the mutant and the parent to detect a difference in their pustule-formation rates. If pustules did not develop at sites inoculated with the mutant and if, among the sites inoculated with the parent, у1 sites per subject formed pustules, we performed accelerating dose-response studies with the mutant. For example, the next 3 subjects were inoculated with target EDDs of the mutant of 100, 200, and 400 cfu. If the mutant did not cause pustules at these doses, we infected groups of 3 subjects until the EDDs of the mutant were 10-to 100-fold higher than that of the parent. The target EDD of the parent was held at ∼55 cfu throughout the study, to prevent disease from progressing too rapidly to permit observation of the subjects. Thus, the mutant-parent comparison was accomplished with 6-12 subjects.
Biopsies. Biopsy specimens were cut into sections. One section was cultured semiquantitatively as described elsewhere [10, 11] . One section was fixed in formalin, and immunohistologic studies were done as described elsewhere [10, 11, 19] . The slides were coded and read by a dermatopathologist who was unaware of the code.
Phenotypes of recovered bacteria. Individual colonies from the inocula, surface cultures, and biopsy samples were selected, suspended in freezing medium, and frozen in 96-well plates. The colonies were scored for susceptibility to chloramphenicol on unsupplemented and chloramphenicol-containing chocolate agar plates. Colonies from the inocula were also tested for growth on chocolate agar and hemoglobin (100 mL/mL) plates. If available, у30 individual colonies were analyzed per specimen. If 30 colonies had the correct phenotype (mutant: Cm r and inability to grow on hemoglobin plates; parent: Cm s and ability to grow on hemoglobin plates), then there was a 95% probability that р11% of the colonies would have the incorrect phenotype in an individual specimen.
Results
Comparison of FX504 with 35000.
In broth containing 50 mg/mL equine hemin (Aldrich, Milwaukee), 35000 and FX504 had similar growth rates (data not shown). Outer-membrane proteins and LOS prepared from FX504 and 35000 were analyzed by use of SDS-PAGE. Both isolates had similar LOS profiles when analyzed on silver-stained gels (data not shown). In Western blot analysis, anti-LOS monoclonal antibody 3F11 bound to identically migrating LOS of both isolates. Outermembrane protein profiles showed that FX504 lacked a 100-kDa band corresponding to HgbA [16] .
Human inoculation experiments.
An escalating doseresponse study was used to compare the virulence of the mutant and the parent. In the first iteration, we inoculated 3 subjects at 3 sites on each arm. Our goal was to inoculate the first arm at 3 sites with EDDs of 25, 50, and 100 cfu of the mutant. The other arm was to be inoculated at 2 sites with an EDD of 55 cfu of the parent and at a 3d site with the highest dose of the mutant that was heat-killed.
Because H. ducreyi clumps in vitro and in vivo, the actual number of cfu in an inoculum can be estimated only by colony counts. The EDDs in the 1st iteration were 53 cfu for 35000 and 20, 40, and 80 cfu for FX504. No lesions developed at sites inoculated with heat-killed bacteria. Papules developed at all 6 sites inoculated with the parent bacteria and at all 9 sites inoculated with the mutant bacteria. Eight of 9 mutant sites resolved (table 1) . Pustules developed at all 6 sites inoculated with the parent bacteria and at 0 of 9 sites inoculated with the mutant bacteria.
The result of the 1st iteration suggested that the mutant's ability to cause pustules was impaired. We therefore infected 3 more subjects and attempted to increase the dose of the mutant. NOTE. Each subject was inoculated at 2 sites with live 35000 and at 3 sites with live FX504. Subjects 101-103 were inoculated in the 1st iteration; subjects 104, 105, and 107 in the 2d iteration; and subjects 108-110 in the 3d iteration.
In the 2d iteration, each subject was inoculated with an EDD of 48 cfu of 35000 and with EDDs of 25, 50, and 100 cfu of FX504. Two papules developed at sites inoculated with 100 cfu of the heat-killed mutant and resolved in 1-3 days. Four of 6 parent sites and 6 of 9 mutant sites developed papules (table  1) . When a clinical end point was reached, 1 parent site and all mutant sites resolved, and 1 parent site remained at the papular stage. Pustules developed at 2 of 6 parent sites and at 0 of 9 mutant sites. Thus, the results of the 1st and 2d iterations were similar, in that the mutant did not cause pustules.
We challenged 3 additional volunteers in the 3d iteration. Each subject was inoculated with an EDD of 60 cfu of 35000 and with EDDs of 125, 250, and 500 cfu of FX504. Volunteers also received 500 cfu of the heat-killed mutant. Three papules developed at sites inoculated with the heat-killed control and resolved in 2-3 days. Papules developed at all parent and mutant sites. Infection in 1 subject (no. 108) was terminated before a clinical end point was reached, because she required antibiotic treatment for cystitis 7 days after inoculation. When the end point was reached (or termination necessitated), 3 parent sites and 5 mutant sites resolved, and 4 mutant sites (3 in subject 108) were papules. Pustules developed at 2 of 6 parent sites and at 0 of 9 mutant sites ( ). Thus, the mutant was P ! .0001 unable to form pustules, even at an EDD 10-fold higher than that of the parent.
Cellular infiltrate of mutant and parent lesions. We examined the cellular infiltrate from 7 parent and 3 mutant sites. In biopsy samples obtained from the parent sites, micropustules with polymorphonuclear leukocytes were present in the epidermis. The dermis contained a perivascular infiltrate of mononuclear cells and some polymorphonuclear leukocytes, and the venules were lined with reactive endothelial cells. The lesions produced by the mutant isolate showed only mononuclear cells in the upper dermis (figure 1). In both the parent and the mutant specimens, the majority of the mononuclear cells stained with a CD3 marker (data not shown).
Recovery of bacteria from lesions. No bacteria were recovered from sites inoculated with the heat-killed organisms. H. ducreyi was recovered intermittently from the surface of the parent sites. The recovery rate of H. ducreyi from cultures obtained from all sites inoculated with the parent ( ) was n = 142 16%, and no H. ducreyi was obtained from sites inoculated with the mutant ( ; . All biopsy samples were culn = 213 P ! .0001 tured semiquantitatively. Bacteria were recovered from 6 of 7 parent biopsy samples and from 0 of 3 mutant biopsy samples. The yield ranged from to ∼ cfu/g of tissue from 5 6 2 ϫ 10 1.5 ϫ 10 the parent biopsy samples. Taken together, the data suggested that the parent bacteria replicated to recoverable quantities in lesions, whereas the mutant bacteria did not.
Confirmation of the phenotype of the recovered bacteria. To confirm that the inocula were correct and that no phenotypic changes occurred during infection, individual colonies from each of the broth cultures used to prepare the inocula, from surface cultures, and from biopsy specimens were analyzed for chloramphenicol susceptibility. If available, у30 individual colonies were analyzed from each specimen. For the 3 parent and 3 mutant broth cultures used to prepare the inocula, all 136 parent colonies and 136 mutant colonies tested were phenotypically correct (mutant, Cm r ; parent, Cm s ). The parent colonies grew on chocolate agar and hemoglobin plates. The mutant colonies grew on chocolate agar plates but not on hemoglobin plates. All 503 colonies obtained from surface cultures and 184 parent colonies obtained from biopsy samples were phenotypically correct (Cm   s   ) . Thus, all colonies tested from the inocula, surface cultures, and biopsy samples had the expected phenotype.
Discussion
Iron limitation is a major obstacle that pathogenic bacteria must overcome to proliferate and produce disease. H. ducreyi is unable to synthesize heme [5, 6] and must be supplied with heme or heme-containing compounds, such as hemoglobin, for growth [7] . H. ducreyi has evolved receptors and transport systems to obtain heme or iron from the host. We compared the virulence of an isogenic hgbA mutant and its parent in human subjects. The mutant formed papules at a rate similar to that of the parent but did not progress to the pustular stage of disease. To our knowledge, this is the 1st demonstration that a putative virulence factor of H. ducreyi may be required for pustule formation in humans. In other trials, the pustule-formation rates for an isogenic hemolysin-deficient mutant and a pilus mutant were similar to those caused by the parent [9, 20] . Our results show that the model can differentiate between virulent and attenuated isolates and that hemoglobin utilization may be required for H. ducreyi pathogenesis.
Although both 35000 and FX504 were able to initiate papule formation, the pustule-formation rate was 55% at the parent sites and 0 at the mutant sites ( ). Pustules formed at P ! .0001 parent sites in a mean SD of days, and volunteers ‫ע‬ 3.2 ‫ע‬ 1.0 were observed for a mean SD of days. In this ‫ע‬ 9.2 ‫ע‬ 3.0 period, 19 of the 24 papules at mutant sites resolved. Thus, the subjects were probably observed for a time sufficient to allow us to observe pustule formation by the mutant if this were to occur. Similarly, in the temperature-dependent rabbit model, an hgbA (hupA) mutant is less virulent than its parent, 35000 [21] . Thus, expression of the hemoglobin receptor appears to be required for virulence in animal and human models of H. ducreyi infection. In the human model, H. ducreyi is shed from sites with established infection but not from sites where infection is transient, and H. ducreyi replicates between the papular and pustular stages of disease [12] . Consistent with these observations, we recovered H. ducreyi intermittently from surface cultures of parent sites but not from mutant sites. H. ducreyi was recovered from most biopsy specimens of parent sites but was never recovered from biopsy specimens of mutant sites. Mutant sites contained a cellular infiltrate, consisting of mononuclear cells, in the upper dermis. Parent sites contained micropustules with polymorphonuclear leukocytes in the epidermis and a perivascular infiltrate of mononuclear cells and some polymorphonuclear leukocytes in the dermis. In both the parent and the mutant specimens, the majority of the mononuclear cells stained with a CD3 marker, as reported elsewhere [9] [10] [11] 19] . Thus, the histopathology of the mutant sites resembled the initial stages of papular infection caused by the parent [19] . These data suggest that FX504 had not replicated enough to elicit the polymorphonuclear cell infiltrate usually caused by the parent as the disease progresses to the pustular stage.
The cutaneous immune response to experimental infection resembles a delayed-type hypersensitivity reaction throughout the papular and pustular stages of infection [19] . Inoculation of heat-killed organisms corresponding to an EDD of 30 cfu does not usually cause erythema [11, 12] , and sites inoculated with heat-killed bacteria (60 cfu) do not contain an inflammatory infiltrate within 24 h of injection [22] . Thus, doses of р60 cfu of heat-killed bacteria are not sufficient to elicit a delayed-type hypersensitivity response, or the antigens eliciting the delayed-type hypersensitivity response are heat-labile products of the bacteria or are synthesized only in vivo. Our inoculations of heat-killed organisms corresponding to an EDD Downloaded from https://academic.oup.com/jid/article-abstract/181/3/1049/908406 by guest on 16 February 2019 of 100-500 cfu caused papule formation at 5 of 6 sites. These papules resolved in 1-3 days. In accordance with our protocol, biopsies were not performed on any of the sites inoculated with heat-killed bacteria, because no disease was present at the clinical end point. We speculate that doses of 100-500 cfu of heatkilled bacteria are sufficient to elicit a transient delayed-type hypersensitivity reaction but that replicating bacteria are necessary to sustain the reaction.
We used an hgbA mutant that contains a cat cassette derived from a mini-Tn3 [23] . We had previously shown that mutants containing this cassette are stable with prolonged laboratory passage in the absence of antibiotic selection [20] . Our institutional review board and our institutional biosafety committee approved the use of mutants containing cat or kan cassettes in human subjects, in consultation with the Office of Recombinant DNA Activities [9] . H. ducreyi expresses cat naturally, and 35000 does not contain the conjugative plasmids found in other H. ducreyi strains [24] . Thus, it is highly unlikely that the cat cassette used in our studies could be transferred to another organism.
We did not test a repaired or a complemented mutant in human subjects. Complementation of H. ducreyi mutants has been achieved in trans by use of the vector pLS88, which has a very broad host range and carries resistance to sulfonamide, streptomycin, and kanamycin [25, 26] . Use of a construct containing a virulence determinant in the pLS88 background poses a risk to the safety of human volunteers and is not permitted in our protocols. Furthermore, it would be difficult to maintain antibiotic selection for a pLS88 construct in a human volunteer. We did not test a mutant complemented in a silent locus on the chromosome, because, to date, no silent locus has been definitively identified. Testing of a repaired mutant would not exclude the possibility of polar effects of the cat insertion in FX504 or the possibility that a secondary mutation occurred during the repair. Thus, we cannot exclude the possibility that the decreased virulence of FX504 was due to a secondary mutation or a polar effect of the cat cassette.
The only observed phenotypic differences between FX504 and the parent are the lack of expression of HgbA in the mutant and the inability of the mutant to grow with hemoglobin as its sole source of heme. Other human pathogens contain multiple genes that undergo phase or antigenic variation. To our knowledge, H. ducreyi genes that are subject to phase or antigenic variation have not been described. However, H. ducreyi autoaggregates, and it is technically difficult to detect phase or antigenic variation of surface proteins or LOS on a colonial level. Although we tested a mutant that was made after limited in vitro passage from its parent, we cannot exclude the possibility that phase or antigenic variation was responsible for the decreased virulence of FX504.
In the experimental model of gonococcal infection in human subjects, a transferrin-receptor mutant is incapable of initiating urethritis [27] . The results of our trial are the 2d demonstration that an iron-uptake system may be required for human infection. H. ducreyi enters the skin through abrasions that occur during intercourse, and puncture of the skin is required to initiate infection in human subjects [10, 28] . H. ducreyi may utilize extracellular hemoglobin from extravasated red blood cells at the sites of trauma. The hgbA mutant is unable to bind or utilize human or animal hemoglobin as a source of heme. Although the hgbA mutant can utilize free hemin in vitro [6, 16] and although it retains an intact TonB-dependent heme receptor [29] , expression of the latter receptor is apparently not sufficient for the organism to replicate and cause disease.
At least 3 other human pathogens express TonB-dependent hemoglobin receptors, as well as multiple receptors for other iron-containing compounds such as transferrin, lactoferrin, and heme. These bacteria include Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae; the latter 2 organisms are capable of expressing various hemoglobin receptors singly or in combination [30] [31] [32] [33] [34] . All of the known functional hemoglobin receptors in these 3 organisms have been shown to undergo frequent phase variation [30, 32, [34] [35] [36] . Phase variation may be used to avoid host immune responses. Alternatively, hemoglobin receptors may be used in different environments, such as the bloodstream, or at certain times of the menstrual cycle. Another mechanism to avoid immune response is to vary the amino acid sequences of receptors among strains. Thus, protective antibodies to the transferrin-binding protein 2 of meningococci show poor cross-strain protection because of the heterogeneity of transferrin-binding protein 2 [37] . In contrast, H. ducreyi expresses 1 hemoglobin receptor, and HgbA is not subject to phase variation [5] . A panel of monoclonal antibodies to 35000 HgbA that recognize 3 distinct epitopes of the protein bind to all strains tested (C.E., unpublished data). Thus, HgbA is highly conserved among H. ducreyi strains.
In summary, this is the 1st demonstration that deletion of a putative virulence factor affects the ability of H. ducreyi to cause human disease. Future studies will be directed at examining whether HgbA or FX504 are suitable vaccine candidates.
